115 related articles for article (PubMed ID: 38651271)
1. Development of an efficient liposomal DOX delivery formulation for HCC therapy by targeting CK2α.
Zhao R; Cheng S; Bai X; Zhang D; Fang H; Che W; Zhang W; Zhou Y; Duan W; Liang Q; Xiao L; Nie G; Hou Y
Biotechnol J; 2024 Apr; 19(4):e2400050. PubMed ID: 38651271
[TBL] [Abstract][Full Text] [Related]
2. A novel targeted delivery system for drug-resistant hepatocellular carcinoma therapy.
Xiao L; Hou Y; He H; Cheng S; Hou Y; Jin H; Song X; Nie G; Hou Y
Nanoscale; 2020 Aug; 12(32):17029-17044. PubMed ID: 32780053
[TBL] [Abstract][Full Text] [Related]
3. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
Wang C; Wei X; Shao G
Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
[TBL] [Abstract][Full Text] [Related]
4. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
[TBL] [Abstract][Full Text] [Related]
5. miR-381 Reverses Multidrug Resistance by Negative Regulation of the
Pu B; Yu X; Cao Y; Li Y; Tang L; Xia J
DNA Cell Biol; 2021 Dec; 40(12):1584-1596. PubMed ID: 34931867
[TBL] [Abstract][Full Text] [Related]
6. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1.
Yang Y; Zhang J; Wu T; Xu X; Cao G; Li H; Chen X
Life Sci; 2019 Jan; 216():200-206. PubMed ID: 30465789
[TBL] [Abstract][Full Text] [Related]
8. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
[TBL] [Abstract][Full Text] [Related]
9.
Diril M; Özdokur KV; Yıldırım Y; Karasulu HY
Pharm Dev Technol; 2023 Dec; 28(10):915-927. PubMed ID: 37921920
[TBL] [Abstract][Full Text] [Related]
10. Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression.
Carabias P; Espelt MV; Bacigalupo ML; Rojas P; Sarrias L; Rubin A; Saffioti NA; Elola MT; Rossi JP; Wolfenstein-Todel C; Rabinovich GA; Troncoso MF
Cell Death Dis; 2022 Jan; 13(1):79. PubMed ID: 35075112
[TBL] [Abstract][Full Text] [Related]
11. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
[TBL] [Abstract][Full Text] [Related]
12. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
[TBL] [Abstract][Full Text] [Related]
13. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
14. Connexin 32 affects doxorubicin resistance in hepatocellular carcinoma cells mediated by Src/FAK signaling pathway.
Yu M; Zou Q; Wu X; Han G; Tong X
Biomed Pharmacother; 2017 Nov; 95():1844-1852. PubMed ID: 28968929
[TBL] [Abstract][Full Text] [Related]
15. TPGS-Galactose-Modified Polydopamine Co-delivery Nanoparticles of Nitric Oxide Donor and Doxorubicin for Targeted Chemo-Photothermal Therapy against Drug-Resistant Hepatocellular Carcinoma.
Du Z; Mao Y; Zhang P; Hu J; Fu J; You Q; Yin J
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35518-35532. PubMed ID: 34286569
[TBL] [Abstract][Full Text] [Related]
16. Dual-Functional Peptide Driven Liposome Codelivery System for Efficient Treatment of Doxorubicin-Resistant Breast Cancer.
Ahmed KS; Liu S; Mao J; Zhang J; Qiu L
Drug Des Devel Ther; 2021; 15():3223-3239. PubMed ID: 34349500
[TBL] [Abstract][Full Text] [Related]
17. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.
Jin F; Wang Y; Li M; Zhu Y; Liang H; Wang C; Wang F; Zhang CY; Zen K; Li L
Cell Death Dis; 2017 Jan; 8(1):e2540. PubMed ID: 28079894
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
20. Circ_0003998 enhances doxorubicin resistance in hepatocellular carcinoma by regulating miR-218-5p/EIF5A2 pathway.
Li X; He J; Ren X; Zhao H; Zhao H
Diagn Pathol; 2020 Dec; 15(1):141. PubMed ID: 33308276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]